Published in Cancer Weekly, April 20th, 2010
"PLD (40 mg/m(2), day I), IFO ( 1700 mg/m(2), infusion clays 1-3), and mesna were given every 28 Clays for 6-9 cycles. Primary endpoint was objective response rate (ORR). Secondary endpoints were response duration, progression free survival (PFS), overall survival (OS), and toxicity. There Were 98...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.